NCT03311672View on ClinicalTrials.gov

T-Cell PET Imaging With [18F]F-AraG in Lung Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 26, 2017

Primary Completion Date

October 15, 2019

Study Completion Date

October 15, 2019

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

[18F]F-Ara-G

Administered after two cycles of immunotherapy +/- stereotactic radiation therapy as part of the PET/CT scan.

DRUG

Pembrolizumab

All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.

RADIATION

PET/CT scan

Scan will be done after two cycles of immunotherapy +/- stereotactic radiation therapy.

Sponsors
All Listed Sponsors
collaborator

CellSight Technologies, Inc.

INDUSTRY

lead

University of California, San Francisco

OTHER